Autor: |
Fuletra JG; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Ristau BT; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Milestone B; Department of Radiology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Cooper HS; Department of Pathology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Browne A; Department of Pathology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Movva S; Department of Medical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Galloway TJ; Department of Radiation Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Lee R; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Waingankar N; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA., Kutikov A; Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA. |